Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Metastatic Cancer 'Thrivers'; Celebrity Cancer Diagnoses; 'Would He Have Lived?'

2.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

3.

Breast cancer prevention: How nurse practitioners and physician assistants can help

4.

As EGFR internalization is decreased, BUB1 controls EGFR signaling.

5.

According to a study, breast cancer cells work together to physically breach barriers and proliferate.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot